Published: Jun 04, 2021
Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE)
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its participation in the 2021 American Transplant Congress (ATC), including two symposia and the presentation of 40 scientific abstracts.
“We look forward to sharing groundbreaking findings from ADMIRAL and KOAR, both multi-center, prospective studies as we continue to drive innovation in transplantation,” said Reg Seeto, President & CEO of CareDx. “These are the first long-term studies on donor-derived cell-free DNA. They are part of 40 scientific abstracts from more than 30 authors, re
Published: Apr 23, 2021
SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) CareDx, Inc., Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced experts will present its latest heart research, which was accepted at the International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, set to take place between April 24-28, 2021.
CareDx’s offerings are showcased through 22 abstracts throughout the ISHLT program. These data selected by the ISHLT organizers, will be presented by prominent thought leaders, highlighting the continued leadership in the cardiothoracic space. Additionally, a CareDx symposium will spotlight leaders in the field of heart and lung transplantation delivering cutting edge content on HeartCare, AlloMap
Allegheny General Hospital Heart Specialists Among the First in the Country to Expand Use of Left Ventricular Assist Device as Bridge to Recovery
Share Article
Cardiothoracic surgeons at Allegheny General Hospital, a part of Allegheny Health Network, are exploring a new indication for left ventricular assist devices as a bridge to recovery from heart failure after performing an explant procedure on a 21-year old patient from western Pennsylvania.
Manreet Kanwar, MD, is an AHN cardiologist who specializes in heart failure; she is also a board member of the International Society of Heart and Lung Transplantation.
“Based on our team’s leading expertise with LVAD technology, we were confident that with the proper pharmacological plan in place, paired with close monitoring, an LVAD could appropriately off-load her left ventricle, allow her heart to heal and put her heart failure into a form of remission.”